Royal Fund Management LLC Invests $98,000 in Eli Lilly And Co (NYSE:LLY)

Royal Fund Management LLC purchased a new position in shares of Eli Lilly And Co (NYSE:LLY) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 707 shares of the company’s stock, valued at approximately $98,000.

Several other large investors have also recently added to or reduced their stakes in LLY. Norges Bank acquired a new position in shares of Eli Lilly And Co during the 4th quarter worth $1,171,509,000. Jennison Associates LLC raised its stake in shares of Eli Lilly And Co by 125.9% during the 1st quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock worth $1,413,841,000 after buying an additional 5,679,574 shares during the last quarter. BlackRock Inc. raised its stake in shares of Eli Lilly And Co by 5.6% during the 1st quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock worth $8,919,623,000 after buying an additional 3,420,265 shares during the last quarter. Capital International Investors raised its stake in shares of Eli Lilly And Co by 3.6% during the 4th quarter. Capital International Investors now owns 26,055,933 shares of the company’s stock worth $3,424,531,000 after buying an additional 910,672 shares during the last quarter. Finally, FMR LLC raised its stake in shares of Eli Lilly And Co by 6.7% during the 4th quarter. FMR LLC now owns 14,235,227 shares of the company’s stock worth $1,870,935,000 after buying an additional 888,413 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

NYSE LLY opened at $151.16 on Friday. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $164.90. The company has a 50-day moving average of $152.85 and a 200-day moving average of $136.00. The company has a debt-to-equity ratio of 4.37, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market cap of $145.65 billion, a P/E ratio of 24.99, a P/E/G ratio of 1.82 and a beta of 0.25.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 23rd. The company reported $1.75 EPS for the quarter, beating the Zacks’ consensus estimate of $1.48 by $0.27. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. The company had revenue of $5.86 billion during the quarter, compared to the consensus estimate of $5.48 billion. During the same quarter in the prior year, the company posted $1.33 EPS. The company’s quarterly revenue was up 15.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Eli Lilly And Co will post 6.81 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.96%. The ex-dividend date of this dividend is Thursday, May 14th. Eli Lilly And Co’s payout ratio is currently 49.01%.

In other news, SVP Stephen F. Fry sold 14,657 shares of the business’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $134.30, for a total transaction of $1,968,435.10. Following the completion of the sale, the senior vice president now owns 110,572 shares in the company, valued at approximately $14,849,819.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Myles O’neill sold 25,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $140.15, for a total value of $3,503,750.00. Following the sale, the senior vice president now owns 44,773 shares of the company’s stock, valued at approximately $6,274,935.95. The disclosure for this sale can be found here. Insiders have sold a total of 906,320 shares of company stock valued at $132,984,238 in the last quarter. Company insiders own 0.09% of the company’s stock.

Several research analysts have recently issued reports on LLY shares. Cantor Fitzgerald lifted their price target on Eli Lilly And Co from $156.00 to $185.00 and gave the stock an “overweight” rating in a research note on Friday, April 24th. Goldman Sachs Group raised shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 target price for the company in a research note on Wednesday, March 11th. Zacks Investment Research cut their target price on shares of Eli Lilly And Co to $156.00 in a research note on Wednesday, April 29th. Mizuho boosted their target price on shares of Eli Lilly And Co from $148.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Finally, Cowen boosted their target price on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $158.64.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Discover Your Risk Tolerance

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.